A tiny gene mutation in human liver cells could one day influence how high or low a dose patients need of about half of the clinically used drugs on the market, new research suggests.
The cause of tuberculosis is Mycobacterium tuberculosis (Mtb), a slow-growing aerobic bacterium that divides every 16 to 20 hours.
Inducing cellular immunity as a means to protect against influenza virus is the focus of several laboratories at the Trudeau Institute.
Merck & Co. said it settled a patent dispute with Glenmark Pharmaceuticals on the cholesterol drug Zetia, one of its best-selling products.
Gilead Sciences, Inc. announced that the company's board of directors has authorized the repurchase of up to $5 billion of the company's common stock through May 2013.
Abbott Laboratories will license at least 24 products in emerging markets through a new unit created to boost sales outside of the U.S., the drug and medical device maker said.
Drugmaker Merck & Co. said that its integration of Schering Plough Corp. is off to a good start, with sales and other operations already combined in the top 20 companies where they operate.
IntelliCyt Corp., a provider of innovative high throughput cell and bead-based screening products for drug discovery and life science research, introduced its new High Throughput Flow Cytometry – HTFC Screening System.
In a bid to meet growing international demand for its liquid handling quality assurance products and services, Artel is expanding into Germany, Switzerland, and Austria, where it will begin offering direct sales and distribution of its Multichannel Verification System and Pipette Calibration System.
Evotec AG announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group, to discover novel small molecule therapeutics.
The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded a grant of $210,300 to Amicus Therapeutics to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer’s disease.
A new study by researchers from McGill University and the University of British Columbia shows that mice, like humans, express pain through facial expressions.
In findings that advance scientists' understanding of a whole class of inherited disorders, The Scripps Research Institute has shed light on a mechanism that enables a potential treatment for Gaucher's disease and other lysosomal storage diseases.
Pramipexole, a dopamine agonist, improves depressive symptoms in patients with Parkinson's disease (PD), and has the potential to become an important antidepressant treatment for these patients.
VBL Therapeutics announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines.